This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 49/3/481    most recent 01.HYP.0000256831.33459.eav1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Park, J.-K. Articles by Muller, D. N. Search for Related Content PubMed PubMed Citation Articles by Park, J.-K. Articles by Muller, D. N. Related Collections Cardiovascular Pharmacology Animal models of human disease Arrythmias-basic studies Other hypertension

(Hypertension. 2007;49:481.)
© 2007 American Heart Association, Inc.

Original Articles

p38 Mitogen-Activated Protein Kinase Inhibition Ameliorates Angiotensin II–Induced Target Organ Damage

Joon-Keun Park; Robert Fischer; Ralf Dechend; Erdenechimeg Shagdarsuren; Andrej Gapeljuk; Maren Wellner; Silke Meiners; Petra Gratze; Nidal Al-Saadi; Sandra Feldt; Anette Fiebeler; Jeffrey B. Madwed; Alexander Schirdewan; Hermann Haller; Friedrich C. Luft; Dominik N. Muller

From the Medical Faculty of the Charité (R.F., R.D., A.G., M.W., S.M., N.A.-S., S.F., A.F., A.S., F.C.L., D.N.M.), Franz Volhard Clinic, HELIOS Klinikum, Berlin, Germany; Max Delbrück Center for Molecular Medicine (P.G., F.C.L., D.N.M.), Berlin-Buch, Germany; Institute for Molecular Cardiovascular Research (E.S.), RWTH Aachen University, University Hospital Aachen, Aachen, Germany; the Medical School of Hannover (J.-K.P., H.H.), Hannover, Germany; and Boehringer-Ingelheim Pharmaceuticals (J.B.M.), Ridgefield, Conn.

Correspondence to Dominik N. Muller, Max-Delbruck Center, Wiltberg Strasse 50, 13125 Berlin, Germany. E-mail dominik.mueller{at}mdc-berlin.de

We investigated whether or not p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II–induced target organ damage. We used double transgenic rats harboring both human renin and angiotensinogen genes (dTGRs). dTGR, with or without p38 inhibitor (BIRB796; 30 mg/kg per day in the diet), and nontransgenic Sprague–Dawley rats were studied in 2 protocols. In protocol 1 (week 7), systolic blood pressure of untreated dTGRs was 204±4 mm Hg, but partially reduced after BIRB796 treatment (166±7 mm Hg), whereas Sprague–Dawley rats were normotensive. The cardiac hypertrophy index was unchanged in untreated and BIRB796-treated dTGRs. The ß-myosin heavy chain expression of BIRB796-treated hearts was significantly lower in BIRB796 compared with dTGRs, indicating a delayed switch to the fetal isoform. BIRB796 treatment significantly reduced cardiac fibrosis, connective tissue growth factor, tumor necrosis factor-, interleukin-6, and macrophage infiltration. Albuminuria was not reduced in BIRB796-treated dTGRs. Tubular and glomerular damage with tumor necrosis factor- expression was unaltered, although serum creatinine and cystatin C were normalized. Renal macrophage infiltration, fibrosis, and vessel damage were reduced. In protocol 2 (week 8), we focused on mortality and arrhythmogenic electrical remodeling. Mortality of untreated dTGRs was 100% but was reduced to 10% in the BIRB796 group. Cardiac magnetic field mapping showed prolongation of depolarization and repolarization in untreated dTGRs compared with Sprague–Dawley rats with a partial reduction by BIRB796. Programmed electrical stimulation elicited ventricular tachycardias in 81% of untreated dTGRs but only in 48% of BIRB796-treated dTGRs. In conclusion, BIRB796 improved survival, target organ damage, and arrhythmogenic potential in angiotensin II–induced target organ damage.

Key Words: angiotensin II • p38 • electrical remodeling • cardiac and renal damage

This article has been cited by other articles:

				R. N. Willette, M. E. Eybye, A. R. Olzinski, D. J. Behm, N. Aiyar, K. Maniscalco, R. G. Bentley, R. W. Coatney, S. Zhao, T. D. Westfall, et al. Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 964 - 970. [Abstract] [Full Text] [PDF]

				W. B.W.H. Melenhorst, G. M. Mulder, Q. Xi, J. G.J. Hoenderop, K. Kimura, S. Eguchi, and H. van Goor Epidermal Growth Factor Receptor Signaling in the Kidney: Key Roles in Physiology and Disease Hypertension, December 1, 2008; 52(6): 987 - 993. [Full Text] [PDF]

				A.-i. Shigenaga, K. Tamura, H. Wakui, S.-i. Masuda, K. Azuma, Y. Tsurumi-Ikeya, M. Ozawa, M. Mogi, M. Matsuda, K. Uchino, et al. Effect of Olmesartan on Tissue Expression Balance Between Angiotensin II Receptor and Its Inhibitory Binding Molecule Hypertension, October 1, 2008; 52(4): 672 - 678. [Abstract] [Full Text] [PDF]

				D. N Muller Mechanisms of hypertension-induced target organ damage Journal of Renin-Angiotensin-Aldosterone System, September 1, 2007; 8(3): 148 - 150. [PDF]